ChemPartner
- Company typePublic
- Founded2002
- HeadquartersSouth San Francisco, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
ChemPartner firmographics
Firmographics- Name
- ChemPartner
- Legal name
- ChemPartner PharmaTech Co., Ltd.
- Website
- https://chempartner.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
ChemPartner industry classification
Industry- Product category
- Contract Research Services (Preclinical Drug Discovery)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- DMPK / ADME & Bioanalysis (HLAGAFAC), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where ChemPartner is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices8 records
Markets served
ChemPartner business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service preclinical research contracts spanning discovery chemistry, biologics discovery, translational biology, bioprocess development, and GLP toxicology. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
ChemPartner product offering
Product offeringCore offering
ChemPartner is a global contract research organization (CRO) providing integrated preclinical drug discovery and development services to pharmaceutical and biotechnology companies. The company operates across four main service categories: Discovery Chemistry (synthetic, peptide, carbohydrate, nucleic acid, PROTAC, and medicinal chemistry with AIDD), Biologics Discovery (antibody discovery/engineering, ADC development, protein production), Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, GLP toxicology), and Bioprocess Development (cell line, process development, and GMP manufacturing). Services span target identification through IND-enabling studies with delivery from eight global facilities.
Product overview
ChemPartner is a global contract research organization (CRO) offering integrated, end-to-end drug discovery and development services. The company operates across four main service categories: Discovery Chemistry (synthetic chemistry, library chemistry, peptide/carbohydrate/nucleic acid chemistry, PROTAC chemistry, medicinal chemistry, computer-aided drug design, and scale-up); Biologics Discovery (antibody discovery and engineering, B cell cloning, hybridoma, phage display, fully human mAb discovery, affinity maturation, ADC development, and protein production); Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, and GLP toxicology); and Bioprocess Development (cell line and process development, scale-up, and GMP manufacturing). The company supports small molecule, biologic, and targeted protein degradation modalities, with a focus on preclinical research from target identification through IND submission.
Differentiator
Problem solved
Functional benefit
Products and services
- Discovery Chemistry Services
- Biologics Discovery Services
- Translational Biology Services
- Bioprocess Development Services
- Computer-Aided Drug Design (AIDD)
Quantifiable outcome
- 90% USA FDA submission supported studies
- +3 more outcomes
Companies that use ChemPartner
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
ChemPartner technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
ChemPartner partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Canterbury Christ Church UniversitycoreCollaboration with Canterbury Christ Church University for the establishment of ChemPartner's first European scientific hub at Discovery Park innovation campus in Sandwich, Kent. The partnership supports preclinical and translational research operations and enables closer collaboration with UK and European partners.
Scale indicators9 records
Recent moves12 records
Expansion highlights6 records
ChemPartner competitors and assessment
Company assessmentEmerging players
- Medpace: Medpace is a mid-sized CRO offering full-service clinical development with growing preclinical capabilities. It is relevant as a comparably-sized, science-focused CRO pursuing an integrated sponsor-partner model similar to ChemPartner's value proposition, though primarily clinical-stage.
- Sai Life Sciences: Sai Life Sciences is an India-based CRO offering discovery, CMC, and biologics services with growing scale. It is comparable as an emerging Asian CRO pursuing an integrated service model and competing for sponsor outsourcing of chemistry, biology, and process development work.
Direct peers
- WuXi AppTec: WuXi AppTec is the largest China-based CRO/CDMO offering end-to-end discovery, development, and manufacturing services. It is the most directly comparable peer to ChemPartner in terms of full preclinical-to-clinical integrated service model, China-based scale, and global sponsor base, though materially larger.
- Tigermed: Tigermed is a leading Chinese clinical CRO with growing preclinical capabilities. While more clinical-focused, it is increasingly expanding into early discovery, making it a relevant China-based peer with overlap in translational biology and integrated sponsor relationships.
- Pharmaron: Pharmaron is a China-headquartered, London-listed CRO offering integrated drug discovery, preclinical, and CMC services with a comparable China-plus-Western footprint. It is one of the closest direct competitors to ChemPartner in preclinical chemistry, DMPK, and safety assessment.
- BioDuro (Sundia Meditech): BioDuro is a China-based CRO/CDMO offering drug discovery, development, and manufacturing services with a similar integrated service menu. It is a direct peer competing for outsourced chemistry, biology, and DMPK work from Western biotech clients.
- WuXi Biologics: WuXi Biologics is a leading global biologics-focused CRO/CDMO providing antibody discovery, cell line development, and GMP manufacturing. It is directly comparable to ChemPartner's Biologics Discovery and Bioprocess Development service lines, particularly around antibody engineering and ADC development.
Broad incumbents
- Charles River Laboratories: Charles River Laboratories is a global, publicly traded CRO offering discovery, safety assessment, and manufacturing services. It is a broad incumbent that competes with ChemPartner's preclinical research, ADME, and biologics service lines, with significantly larger scale and deeper Western sponsor relationships.
- IQVIA: IQVIA is a global life sciences services leader offering R&D, clinical, real-world evidence, and commercial services. While primarily clinical-focused, its R&D Solutions division overlaps with ChemPartner's preclinical offerings, and it represents a benchmark for integrated sponsor relationships.
- Labcorp Drug Development: Labcorp Drug Development (formerly Covance) is a large diversified CRO offering preclinical, clinical, and central laboratory services. It competes with ChemPartner in preclinical toxicology, ADME, and bioanalytical work and has substantially greater scale and Western sponsor presence.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
ChemPartner social profiles
Digital presenceChemPartner financial estimates
Financial estimateRevenue estimate
Valuation estimate
ChemPartner leadership team
Management profileNumber of profiles
Profiles8 records
ChemPartner funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ChemPartner M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ChemPartner
What does ChemPartner do?
ChemPartner is a global contract research organization (CRO) providing integrated preclinical drug discovery and development services to pharmaceutical and biotechnology companies. The company operates across four main service categories: Discovery Chemistry (synthetic, peptide, carbohydrate, nucleic acid, PROTAC, and medicinal chemistry with AIDD), Biologics Discovery (antibody discovery/engineering, ADC development, protein production), Translational Biology (molecular biology, biochemistry, in vitro and in vivo pharmacology, ADME/PK-PD, GLP toxicology), and Bioprocess Development (cell line, process development, and GMP manufacturing). Services span target identification through IND-enabling studies with delivery from eight global facilities.
Is ChemPartner a public or private company?
ChemPartner is a public company. It is classified as public and is currently operating.
When was ChemPartner founded?
ChemPartner was founded in 2002. It employs 1,001 to 5,000 people.
Where is ChemPartner based?
ChemPartner is headquartered in South San Francisco, United States, in the North America region.
How does ChemPartner make money?
One revenue line is on record: contract Research Services.
Who are ChemPartner's main competitors?
Emerging players on record are Medpace and Sai Life Sciences. Direct peers are WuXi AppTec, Tigermed, Pharmaron, BioDuro (Sundia Meditech) and WuXi Biologics. Broad incumbents are Charles River Laboratories, IQVIA and Labcorp Drug Development.
Does ChemPartner have an API?
No public API is recorded for ChemPartner.
What industry is ChemPartner in?
ChemPartner's product category is Contract Research Services (Preclinical Drug Discovery). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.